Obsidian Therapeutics OBX
Drug Manufacturers - General, Healthcare
$14.43
−2.43%
- Market cap
- $891.4M
- PE
- n/m
- not a meaningful number
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q2 FY26 |
|---|---|
| Net income | $0 |
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Obsidian Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| OBXObsidian Therapeutics | $891.4M | n/m | n/a | n/m | n/m | n/m | |
| ABUSArbutus Biopharma | $791.4M | 5.1× | 5.6× | 4.4× | n/m | 84.2% | |
| COLLCollegium Pharmaceutical | $770.9M | 19.1× | 19.1× | 1.0× | +14% | 5.9% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 15.9× | 20.5× | 1.6× | +1% | 10.8% | |
| OMEROmeros | $1.3B | 11.7× | 11.7× | n/m | n/m | n/m | |
| ZVRAZevra Therapeutics | $599.8M | 10.9× | 12.2× | 4.4× | +119% | 42.8% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.8× | 1.5× | +26% | 33.4% | |
| ANABAnaptysbio | $1.4B | 10.3× | 99.3× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.7× | 1.9× | +6% | 2.0% | |
| PBYIPuma Biotechnology | $525.5M | 19.6× | 12.3× | 2.3× | −3% | 11.6% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| Peer median | $970.6M | 13.8× | 17.0× | 1.8× | +14% | 11.2% |
More on Obsidian Therapeutics
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .